A detailed history of Hhlr Advisors, Ltd. transactions in I Mab stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 6,909,220 shares of IMAB stock, worth $6.7 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
6,909,220
Previous 6,909,220 -0.0%
Holding current value
$6.7 Million
Previous $11.5 Million 25.75%
% of portfolio
0.2%
Previous 0.3%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$2.95 - $3.85 $133,404 - $174,104
-45,222 Reduced 0.65%
6,909,220 $20.7 Million
Q1 2023

May 15, 2023

SELL
$3.08 - $7.39 $703,496 - $1.69 Million
-228,408 Reduced 3.18%
6,954,442 $24.1 Million
Q3 2021

Nov 15, 2021

BUY
$57.18 - $84.43 $32.4 Million - $47.8 Million
566,680 Added 8.57%
7,182,850 $521 Million
Q1 2021

May 17, 2021

BUY
$44.38 - $63.97 $227 Million - $328 Million
5,119,630 Added 342.1%
6,616,170 $321 Million
Q3 2020

Nov 16, 2020

BUY
$27.46 - $47.03 $41.1 Million - $70.4 Million
1,496,540 New
1,496,540 $70.4 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $80.6M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Hhlr Advisors, Ltd. Portfolio

Follow Hhlr Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Hhlr Advisors, Ltd. with notifications on news.